Welcome to our dedicated page for Check Cap news (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
Check-Cap Ltd. reports developments as an Israel-incorporated clinical-stage medical diagnostics company with Nasdaq-listed ordinary shares. Recurring news for CHEK centers on shareholder voting matters, governance actions, material agreements, capital-structure proposals, clinical or regulatory disclosures, and operating and financial results.
Company updates also include annual meeting outcomes, board and proxy matters, transaction-related disclosures, and public-company status issues tied to its reporting obligations and exchange listing requirements.
MBody AI (NASDAQ: CHEK) said Check-Cap shareholders approved merger-related proposals with over 98% of votes, accelerating the company's transformation into a hardware-agnostic embodied AI provider. The merger is expected to close in the coming weeks, subject to customary closing conditions. MBody AI will operate the MBody AI Orchestrator platform to coordinate robots and sensors across hospitality, healthcare, logistics, retail, and data centers.
MBody AI (NASDAQ: CHEK) announced major enterprise deployments, multi-year, multi-million-dollar contracts, and growing investor interest ahead of a merger vote on November 14, 2025 that would combine Check-Cap with MBody AI.
The release highlights the MBody AI Orchestrator as a hardware-agnostic platform deployed at Fortune 500 clients, citing up to 40% labor reduction, 80% uptime improvement, and accelerating global adoption with "hundreds of millions" in investor interest.
Check-Cap (NASDAQ: CHEK) announced it rescheduled its Annual General Meeting to November 14, 2025 and provided an update on the proposed business combination with MBody AI. The companies executed a Merger Agreement on September 12, 2025 under which Merger Sub will merge into MBody AI, making MBody AI a wholly owned subsidiary of Check-Cap, subject to shareholder approval and closing conditions.
Key transactional details: the Board affirmed the originally disclosed exchange ratio; a proposed reverse share split range of 1-for-2 to 1-for-100; authorized ordinary shares will remain at 18,000,000 with nominal value NIS 48.0; record date for voting was September 16, 2025. MBody AI reports material inbound demand and says investor inquiries reached hundreds of millions of dollars. If approved, the company plans a name change to "MBody AI Ltd." and intends cross-listing and further institutional alignment post-close.
Check-Cap (NASDAQ:CHEK) has entered into a definitive merger agreement with MBody AI, creating a combined company focused on embodied AI for the autonomous workforce. Under the agreement, MBody AI shareholders will own 90% of the combined company, while Check-Cap shareholders will retain 10% on a fully diluted basis.
The merged entity, to be renamed MBody AI Ltd., will operate in the embodied-AI market, which Morgan Stanley forecasts to reach $40 Trillion by 2050. MBody AI specializes in developing proprietary AI technology for intelligent systems, initially focusing on hospitality with plans to expand into warehousing, office management, and healthcare. Check-Cap's legacy business, including patents and proprietary medical equipment, will continue as part of the combined company.
The merger requires Check-Cap shareholder approval at the October 17, 2025 Annual General Meeting. Additionally, Check-Cap must address a Nasdaq compliance issue regarding minimum stockholders' equity by October 20, 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.